⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14035429 | 0.82 | — | — | |
| SCHEMBL194036 | 0.80 | ALDH1A1 (0.35) | — | |
| Phosphoric Acid SCHEMBL3920845 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL14702928 | 0.75 | ALDH1A1 (0.34) | — | |
| SCHEMBL22923956 | 0.73 | TSHR (0.48) | — | |
| Bicarbonate SCHEMBL28331476 | 0.73 | — | — | |
| SCHEMBL23095493 | 0.70 | TSHR (0.30) | — | |
| SCHEMBL19625568 | 0.70 | CTSA (0.32) | — | |
| SCHEMBL990567 | 0.69 | — | — | |
| SCHEMBL10160976 | 0.69 | PEPD (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018185-A1 | Synthesis of 2,4-Pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8299242-B2 | Synthesis of 2,4-pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120208785-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8227455-B2 | Methods of treating cell proliferative disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8211889-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211888-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120108810-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110319613-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110003986-A1 | Synthesis of 2,4-Pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7449458-B2 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades; tyrosine kinase Syk kinase inhibitor; collagen-induced platelet activation inhibitor | RIGEL PHARMACEUTICALS, INC. (US) | 2008-11-11 | — | — | US | disclosed |